Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of HY-021068 in systemic sclerosis
ChiCTR2500099930Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of piragrel sodium in systemic sclerosis (SSc), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change from baseline in modified Rodnan Skin Score. Started Apr 2025; status: recruiting.
02
Drugs
piragrel sodium
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on ChiCTR2500099930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099930.